PTON shorts retreat after earnings beat, but Street remains split
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Peloton Interactive just posted a meaningful earnings beat — and the short sellers are responding, with a significant short-covering rally visible in the data over the past three weeks.
Short interest has dropped sharply from its early April peak. SI % FF hit 16.6% at end-March, climbed further to 16.4% in early April, then tumbled hard through late April after earnings came through on May 7. The print delivered a 9.4% next-day jump in the stock. As of this week, SI % FF has compressed to roughly 12.7% — a fall of nearly four percentage points from the April peak — with the stock now trading at $5.69, up 18% over the past month.
The borrow market confirms a relaxed setup. Cost to borrow has eased to just 0.39%, down 12% over the past week and well off the 0.57% levels seen in early April. Availability is generous — borrow supply is plentiful relative to what's actually lent out, which is a far cry from the tighter conditions of mid-April. The ORTEX short score of 56.2 is moderate and has barely moved over the past two weeks, consistent with a market that is covering rather than pressing new short bets. Options corroborate the calmer tone: the put/call ratio at 0.41 is only marginally above its 20-day average of 0.39, with a z-score under 0.7 — no material hedging signal.
The Street pivoted quickly after the earnings beat. Goldman Sachs raised its target from $7 to $8 on May 8, maintaining Buy, while Macquarie lifted from $6 to $7 the same day, also keeping Outperform. Both moves land with the stock at $5.69 — implying meaningful upside to consensus. The mean analyst target now stands at $7.97, roughly 40% above current levels. That said, Citi and JP Morgan cut targets sharply in February following the prior quarter's miss, moving to $5 and $6 respectively on Neutral ratings. The bull case centres on cost discipline, sustained free cash flow, and a 51.5% gross margin. The bear case focuses on declining revenue — top-line fell 6% year-on-year last quarter — and the fragility of a subscription-heavy model if membership churn accelerates. The EV/EBITDA multiple on a trailing basis is 13.2x, not cheap for a business still shrinking.
Institutional ownership adds a layer of interest. T. Rowe Price added more than 1.4 million shares in Q1, bringing its stake to 4.2% of the company. Eminence Capital and D.E. Shaw also added materially in the prior quarter, having built positions of around 4.2% and 4.0% respectively. That cluster of active-manager buying through Q4 2025 and into Q1 2026 provided a base for the stock even as short interest climbed to its peak. Insider activity has been the reverse — the COO trimmed twice in April following a stock award, and the CFO sold a small tranche in March — though the values involved are modest and the 90-day net insider position is marginally positive at roughly $4.2 million in value.
Earnings history sharpens the risk picture. The February 2026 print moved the stock down 21.7% the next day and 28.4% over five days — a severe reaction to that quarter's miss. The May 7 print reversed that dynamic, up 9.4%. The next earnings event is not scheduled until August 20, which gives the stock a relatively long run without a binary catalyst. The key question heading into that window is whether the current revenue decline stabilises or steepens — the Q3 print will be the first real test of whether the May recovery represents a turning point or a temporary relief bounce.
Stocks in this article
See the live data behind this article on ORTEX.
Open PTON on ORTEX →How this article was generated
- Generated
- 9 May 2026, 20:42
- Data as of
- 9 May 2026, 20:41
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signals
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.